Navigation Links
Prednisone tablets less variable than marketed drugs
Date:4/1/2008

Rockville, Md., April 1, 2008 The U.S. Pharmacopeial (USP) Convention today announced results of a study comparing the dissolution variability of USP Prednisone Lot P Reference Standard tablets to two marketed drugs. Study results clearly show less variability in USP Prednisone Lot P tablets than in the marketed tablets. Dissolution testing of solid oral dosage forms plays a critical role in drug manufacturing because it indicates whether a drug will dissolve properly in the body. This in turn is an established criterion in quality assurance and regulation of manufactured drugs and dietary supplements.

In all analytical testing, including dissolution, the apparatus used must undergo installation, operation and performance qualification to ensure reliable results. These activities are detailed in various USP General Chapters, particularly Dissolution <711>. For dissolution testing, the performance verification test involves USP Prednisone Reference Standard tablets. The current study explored quality attributes of USP Lot P Prednisone Reference Standard tablets in comparison to two commercially available drugs that are marketed in tablet form.

The study was undertaken in response to assertions that the USP Prednisone Lot P Reference Standard tablets yielded highly variable results and led to unreliable dissolution test results. It compared the dissolution variability associated with selected commercial dosage forms to that of USP Lot P Prednisone Reference Standard tablets. The study was conducted according to metrological principles established by the International Organization for Standardization.

I am very pleased that the results of this testing showed significantly less variability in the USP Lot P Prednisone Reference Standard tablets than in the comparator tablets, said William Koch, Ph.D, chief reference materials officer for USP. USP Prednisone yielded an average variability of less than five percent, while comparators averaged about 13 percent. Established metrological principles were followed to ensure the tests objectivity, and it is clear that USP Prednisone Reference Standard tablets are not the cause of variation in dissolution test results, Dr. Koch continued. Manufacturers should be assured of the appropriate performance of the USP Prednisone tablets in dissolution testing.


'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Related biology news :

1. Variable light illuminates the distribution of picophytoplankton
2. Ant guts could pave the way for better drugs
3. Simplifying manufacture of drugs, plastics earns UH chemist top honor
4. Pharmaceutical breakthrough may make a range of drugs cheaper and more available
5. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
6. Physician-scientist urges improved drug regulation to ensure heart safety of non-heart drugs
7. Cheaper drugs now closer to realization with new DropArray technology
8. Club drugs inflict damage similar to traumatic brain injury
9. MIT: Remote-control nanoparticles deliver drugs directly into tumors
10. Market testing of dietary supplements and drugs underscores value of USPs public health programs
11. Scientists unveil structure of molecular target of many drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... is apparently one of the most popular hubs ... Project, MetaHIT and other huge studies of human ... that past few years, the microbiome space has ... applied biomedical research. This report focuses on ...
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... MO (PRWEB) , ... February 10, 2016 , ... ... will attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st ... ISPE is expecting to fill more than 100 tables for its annual event, ...
(Date:2/10/2016)... Mateo, CA (PRWEB) , ... February 10, 2016 ... ... of Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads ... September 2014. More than 1,600 participants have joined the PROMPT study, which seeks ...
(Date:2/10/2016)... La Jolla CA (PRWEB) , ... February 10, 2016 , ... ... of new agents for the treatment of Alzheimer’s disease, announced today it has been ... to February 18th at the Breakers in Palm Beach, Florida. The purpose of ...
Breaking Biology Technology: